{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:57:43Z","timestamp":1790618263151,"version":"4.1.0"},"posted":{"date-parts":[[2026,9,24]]},"group-title":"Microbiology","reference-count":45,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["R61AI161809"],"award-info":[{"award-number":["R61AI161809"]}]},{"name":"NIH","award":["R33AI161809"],"award-info":[{"award-number":["R33AI161809"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Rationale<\/jats:title>\n                  <jats:p>Tuberculosis preventive therapy (TPT) is essential for global tuberculosis control, yet estimated coverage remains well below global targets. Current World Health Organization (WHO)-recommended regimens require 1-9 months of treatment and are associated with suboptimal completion rates. Long-acting injectable (LAI) formulations offer the potential to improve TPT uptake and completion, with ideal products providing \"one-and-done\" options via a single administration. Sorfequiline, a second-generation diarylquinoline with superior potency over bedaquiline and lower QT prolongation risk, is a promising candidate for LAI TPT.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To experimentally determine exposure-activity relationships for sorfequiline as TPT, estimate target plasma exposures, and characterize the pharmacokinetics (PK), tolerability, and efficacy of sorfequiline LAI formulations.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Oral sorfequiline dosing experiments established PK and pharmacodynamic relationships in a validated paucibacillary mouse model of TPT. Three candidate sorfequiline LAI formulations were evaluated for PK and tolerability in uninfected mice, followed by efficacy assessment compared to oral comparators (1HP, bedaquiline, sorfequiline).<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Measurement and Main Results<\/jats:title>\n                  <jats:p>\n                    Oral dosing experiments established a provisional target plasma C\n                    <jats:sub>min<\/jats:sub>\n                    of 35 ng\/mL for bactericidal effect. All tested LAI formulations achieved this target for at least 4 weeks post-dose. In efficacy studies, all sorfequiline LAI regimens (62.5-250 mg\/kg) and sorfequiline oral regimens demonstrated significantly greater bactericidal activity than 1HP and oral bedaquiline. Among mice receiving \u2265125 mg\/kg of any sorfequiline LAI, 92% were culture-negative at 12 weeks.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Superior efficacy of a single-dose sorfequiline LAI injection compared to 1HP indicates the potential to meet the WHO target product profile for an optimal \"one-and-done\" LAI TPT clinical regimen.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.22.752266","type":"posted-content","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:05:17Z","timestamp":1790294717000},"source":"Crossref","is-referenced-by-count":0,"title":["One-Dose Efficacy of Long-Acting Sorfequiline in a Mouse Model of Tuberculosis Preventive Therapy"],"prefix":"10.64898","author":[{"given":"Si-Yang","family":"Li","sequence":"first","affiliation":[{"name":"Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Hobson","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"},{"name":"Department of Chemistry, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9359-9144","authenticated-orcid":false,"given":"Nicole C.","family":"Ammerman","sequence":"additional","affiliation":[{"name":"Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"Erasmus MC, University Medical Center Rotterdam, Department of Medical Microbiology and Infection Diseases, Rotterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Pertinez","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"},{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Sharp","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"},{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Fotouhi","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6946-1097","authenticated-orcid":false,"given":"Steve","family":"Rannard","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"},{"name":"Department of Chemistry, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Centre for Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, UK"},{"name":"Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1440-9889","authenticated-orcid":false,"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for TB Research, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026092810150788000_2026.09.22.752266v1.1","unstructured":"Stop TB Partnership. The global plan to end TB 2023-2030. 2022. https:\/\/www.stoptb.org\/what-we-do\/advocate-endtb\/global-plan-end-tb\/global-plan-end-tb-2023-2030"},{"key":"2026092810150788000_2026.09.22.752266v1.2","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis Module 1: prevention - tuberculosis preventive treatment, second edition. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240096196"},{"key":"2026092810150788000_2026.09.22.752266v1.3","unstructured":"World Health Organization. Global tuberculosis report 2024. 2024. https:\/\/www.who.int\/publications\/i\/item\/9789240101531"},{"key":"2026092810150788000_2026.09.22.752266v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2314325"},{"key":"2026092810150788000_2026.09.22.752266v1.5","unstructured":"World Health Organization. WHO operational handbook on tuberculosis. Module 4: treatment and care. 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240108141"},{"key":"2026092810150788000_2026.09.22.752266v1.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202012-4541OC"},{"key":"2026092810150788000_2026.09.22.752266v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00007-19"},{"key":"2026092810150788000_2026.09.22.752266v1.8","unstructured":"Johns Hopkins University. Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (BREACH-TB). ClinicalTrials.gov Identifier: NCT06568484 . NIH, US National Library of Medicine. Updated 03 June 2026. Accessed 05 June 2026, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06568484"},{"key":"2026092810150788000_2026.09.22.752266v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac672"},{"key":"2026092810150788000_2026.09.22.752266v1.10","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0486"},{"key":"2026092810150788000_2026.09.22.752266v1.11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf426"},{"key":"2026092810150788000_2026.09.22.752266v1.12","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.24.0670"},{"key":"2026092810150788000_2026.09.22.752266v1.13","unstructured":"World Health Organization. Target product profiles for tuberculosis preventive treatment. Geneva: World Health Organization,; 2020."},{"key":"2026092810150788000_2026.09.22.752266v1.14","unstructured":"Janssen Cilag International. A Single Ascending Dose, Single-Centre Study, to Assess Pharmacokinetics, Safety and Tolerability of a Single Intramuscular Dose of Bedaquiline Long-Acting Injection Formulation in Healthy Participants. EUCT number: 2023-508810-41-00. Protocol Code: TMC207TBC1006. . European Union Clinical Trials (EUCT),. Accessed 21 July 2025, 2025. https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2023-508810-41-00?lang=en"},{"key":"2026092810150788000_2026.09.22.752266v1.15","unstructured":"Cox V. Update on J&J Innovative Medicine Long-Acting Formulations for Tuberculosis. presented at: Long-Acting\/Extended Release Antiretroviral Research Resource Program (LEAP) Investigator Meeting and Annual Workshop 2025; 2025; San Francisco, California, USA. Session Plenary Session 1: Current Status of Existing Technologies. https:\/\/longactinghiv.org\/LEAP-WORKSHOP_3-8-2025; https:\/\/longactinghiv.org\/files\/inline-files\/Vivian_Cox.mp4"},{"key":"2026092810150788000_2026.09.22.752266v1.16","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.17.0515"},{"key":"2026092810150788000_2026.09.22.752266v1.17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac685"},{"key":"2026092810150788000_2026.09.22.752266v1.18","unstructured":"Zeitlinger M , Prager M , Guinard-Azadian C , et al. Bedaquiline long-acting formulation: Interim results of a phase 1 pharmacokinetic and safety study for single-dose TB preventive treatment (Abstract LB02-1321-19). presented at: World Conference on Lung Health; 2025 2025; Copenhagen, Denmark. Session LB02 The Union\/CDC Late-Breaker Session - Clinical Trial Advances in TB: HIV Co-Infection, Pediatric Meningitis, and New Drugs. https:\/\/unionconf2025.abstractserver.com\/programme\/#\/details\/presentations\/2420"},{"key":"2026092810150788000_2026.09.22.752266v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00405-2"},{"key":"2026092810150788000_2026.09.22.752266v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2026.114806"},{"key":"2026092810150788000_2026.09.22.752266v1.21","unstructured":"TB Alliance. Long-Acting Injectables. TB Alliance,. Updated 2026. Accessed 25 June 2026, 2026. https:\/\/www.tballiance.org\/compound\/portfolio-compound-long-acting-injectables\/"},{"key":"2026092810150788000_2026.09.22.752266v1.22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01412-21"},{"key":"2026092810150788000_2026.09.22.752266v1.23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae332"},{"key":"2026092810150788000_2026.09.22.752266v1.24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00613-24"},{"issue":"3","key":"2026092810150788000_2026.09.22.752266v1.25","doi-asserted-by":"crossref","first-page":"e0127325","DOI":"10.1128\/aac.01273-25","article-title":"Cardiodynamic evaluation of sorfequiline (TBAJ- 876): results from a first-in-human study","volume":"70","year":"2026","journal-title":"Antimicrob Agents Chemother."},{"key":"2026092810150788000_2026.09.22.752266v1.26","unstructured":"Global Alliance for TB Drug Development (Responsible Party). Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis. ClinicalTrials.gov Identifier: NCT06058299 . NIH, US National Library of Medicine. Accessed 21 July 2025, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06058299"},{"key":"2026092810150788000_2026.09.22.752266v1.27","unstructured":"Olugbosi M , Beumont M , Lombard L , et al. Safety and efficacy of TBAJ-876 in combination with pretomanid and linezolid: Week 8 analysis result of NC-009 (Abstract OA26-349-21). presented at: World Conference on Lung Health; 18-21 November 2025 2025; Copenhagen, Denmark. Session OA26 Advancing TB care: Innovations in drugs, vaccines, diagnostics and treatment. https:\/\/unionconf2025.abstractserver.com\/programme\/#\/details\/presentations\/109"},{"key":"2026092810150788000_2026.09.22.752266v1.28","doi-asserted-by":"publisher","DOI":"10.1039\/d1nr00309g"},{"key":"2026092810150788000_2026.09.22.752266v1.29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.250480397"},{"key":"2026092810150788000_2026.09.22.752266v1.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201103-0397OC"},{"key":"2026092810150788000_2026.09.22.752266v1.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200905-0795OC"},{"key":"2026092810150788000_2026.09.22.752266v1.32","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00481-23"},{"key":"2026092810150788000_2026.09.22.752266v1.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"2026092810150788000_2026.09.22.752266v1.34","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00035-23"},{"key":"2026092810150788000_2026.09.22.752266v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.111932"},{"key":"2026092810150788000_2026.09.22.752266v1.36","unstructured":"Global Alliance for TB Drug Development (Responsible Party). Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults. ClinicalTrials.gov Identifier: NCT04493671. NIH, US National Library of Medicine. Updated 04 June 2025. Accessed 04 February 2026, 2026. https:\/\/clinicaltrials.gov\/study\/NCT04493671"},{"key":"2026092810150788000_2026.09.22.752266v1.37","doi-asserted-by":"publisher","DOI":"10.4155\/tde.11.19"},{"key":"2026092810150788000_2026.09.22.752266v1.38","unstructured":"Calderin JM , Nedelman J , Salinger DH , Vongjarudech T , Denti P , Svensson EM. Semi-mechanistic population pharmacokinetic modelling of the novel antituberculosis drug TBAJ-876 and its metabolite M3 in healthy volunteers (Abstract 11359). presented at: Population Approach Group Europe (PAGE); 2025; Thessaloniki, Greece. Session Drug\/Disease Modelling - Infection. https:\/\/www.page-meeting.org\/default.asp?abstract=11359"},{"key":"2026092810150788000_2026.09.22.752266v1.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf701"},{"key":"2026092810150788000_2026.09.22.752266v1.40","doi-asserted-by":"publisher","DOI":"10.1093\/jpids\/pit077"},{"key":"2026092810150788000_2026.09.22.752266v1.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2489OC"},{"key":"2026092810150788000_2026.09.22.752266v1.42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00720-11"},{"key":"2026092810150788000_2026.09.22.752266v1.43","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00615-24"},{"key":"2026092810150788000_2026.09.22.752266v1.44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf088"},{"key":"2026092810150788000_2026.09.22.752266v1.45","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0667"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.22.752266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:15Z","timestamp":1790615715000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.22.752266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":45,"URL":"https:\/\/doi.org\/10.64898\/2026.09.22.752266","relation":{},"subject":[],"published":{"date-parts":[[2026,9,24]]},"subtype":"preprint"}}